Picture of Protagonist Therapeutics logo

PTGX — Protagonist Therapeutics News Story

0.000.00%
us flag iconLast trade - 00:00
HealthcareAdventurousLarge CapHigh Flyer

Brief: Protagonist Therapeutics Q3 EPS USD 3.07




BRIEF-Protagonist Therapeutics Q3 EPS USD 3.07


Nov 05 (Reuters) - Protagonist Therapeutics Q3 operating expenses USD 56.078 million.

  • Q3 net income USD 220.015 million
  • Q3 license and collaboration revenue USD 274.41 million
  • Q3 income from operations USD 218.332 million

Recent news on Protagonist Therapeutics

See all news